Sorafenib (SOR) — Competitive Intelligence Brief

Sorafenib (SOR) (Sorafenib (SOR)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-kinase inhibitor; RAF/VEGFR/PDGFR inhibitor. Area: Oncology.

marketed Multi-kinase inhibitor; RAF/VEGFR/PDGFR inhibitor RAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT Oncology Small molecule

Target snapshot

Sorafenib (SOR) (Sorafenib (SOR)) — The University of Texas Health Science Center at San Antonio. Sorafenib is a multi-kinase inhibitor that blocks several protein kinases involved in tumor cell proliferation and angiogenesis, including RAF, VEGFR, and PDGFR.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sorafenib (SOR) TARGET	Sorafenib (SOR)	The University of Texas Health Science Center at San Antonio	marketed	Multi-kinase inhibitor; RAF/VEGFR/PDGFR inhibitor	RAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib Standard Dosing Regimen	Sorafenib Standard Dosing Regimen	University of Florida	marketed	Multi-kinase inhibitor	BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib Ramp-Up Regimen	Sorafenib Ramp-Up Regimen	University of Florida	marketed	Multi-kinase inhibitor	BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib (SORA)	Sorafenib (SORA)	Nanfang Hospital, Southern Medical University	marketed	Multi-kinase inhibitor	RAF, VEGFR-2, VEGFR-3, PDGFR-β
TAS-102, Regorafenib , Fruquintinib	TAS-102, Regorafenib , Fruquintinib	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Nucleoside analog, Multi-kinase inhibitor, VEGFR2 inhibitor	Thymidylate synthase, VEGFR2
Sorafenib + Pravastatin	Sorafenib + Pravastatin	Centre Hospitalier Universitaire Dijon	phase 3	Multi-kinase inhibitor + HMG-CoA reductase inhibitor	RAF, VEGFR, PDGFR (sorafenib); HMG-CoA reductase (pravastatin)
Sorafenib with Low-dose FP	Sorafenib with Low-dose FP	Ministry of Health, Labour and Welfare, Japan	phase 3	Multi-kinase inhibitor + chemotherapy combination	RAF kinase, VEGFR, PDGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-kinase inhibitor; RAF/VEGFR/PDGFR inhibitor class)

1. The University of Texas Health Science Center at San Antonio · 1 drug in this class